European All-comers' Multicentric Prospective REGISTRY on LUMINOR© Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up.

This European registry is tracking 5-year outcomes of patients treated with the LUMINOR Drug-Eluting Balloon (DEB) for blockages in the superficial femoral artery (SFA) and popliteal artery — the main arteries supplying blood to the leg. Peripheral artery disease (PAD) in these arteries causes pain when walking (claudication) or even at rest, and can threaten limb survival in severe cases. Drug-eluting balloons are inflated inside the blocked artery and release a drug (paclitaxel) that prevents the artery from narrowing again. The registry collects real-world data from multiple European centers over 5 years to assess how well the LUMINOR DEB works in clinical practice — measuring outcomes like freedom from target lesion revascularization, amputation rates, and walking ability. This long-term data is important for establishing evidence around this device. You may be eligible if: - You are 18 or older - You have significant (70%+ stenosis or occlusion) of a native superficial femoral or popliteal artery - You have claudication or more severe leg symptoms (Rutherford categories 2–5) - You have had successful guidewire crossing and balloon pre-dilation of the lesion - You are willing to give informed consent and attend 5 years of follow-up You may NOT be eligible if: - You are pregnant, breastfeeding, or planning pregnancy - You are contraindicated for the LUMINOR DEB per its instructions for use - You have a life expectancy of less than 1 year - You are currently in another investigational study - You have an acute vessel occlusion or visible blood clot in the target vessel Talk to your doctor to see if this trial is right for you.